Stockreport

GSK Presents New Data from the GARNET Study Demonstrating Potential of Dostarlimab to Treat a Subset of Women with Recurrent or Advanced Endometrial Cancer

GlaxoSmithKline PLC  (GSK) 
US:NYSE Investor Relations: gsk.com/en-gb/investors
PDF Data accepted as a late-breaking abstract and presented as a webinar as part of the Society of Gynecologic Oncology 2020 virtual congressPatients in the updated analysis [Read more]